AAVOGEN INC
Rockville, MD · Biotech · Private
Engineered AAV capsids with enhanced muscle tropism and reduced liver off-target binding for gene therapy
aavogen.com →- Grants
- $9.0M
- 14 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 3
- 0 granted · 3 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20172019202120232025
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · AVGN7, a Novel Gene Therapeutic for Treating Cancer Cachexia | $1,206,955 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · AVGN7, a Novel Gene Therapeutic for Treating Cancer Cachexia | $2,002,000 | |
| Federal grant | Department of Health and Human Services · Phase II · AVGN7, a Novel Gene Therapeutic for Treating Cancer Cachexia | $660,235 | |
| Federal grant | Department of Health and Human Services · Phase I · Preclinical Validation of AVGN7 for Treating Duchenne Muscular Dystrophy | $224,999 | |
| Federal grant | Department of Health and Human Services · Phase I · Preclinical Validation of AVGN7 for Treating Duchenne Muscular Dystrophy | $224,999 | |
| Federal grant | Department of Health and Human Services · Phase II · AVGN7, a Novel Gene Therapeutic for Treating Cancer Cachexia | $1 | |
| Federal grant | Department of Health and Human Services · Phase II · AVGN7, a Novel Gene Therapeutic for Treating Cancer Cachexia | $134,809 | |
| Federal grant | Department of Health and Human Services · Phase II · Preclinical Development of a Novel Gene Therapeutic for Inclusion Body Myositis | $904,058 | |
| Federal grant | Department of Health and Human Services · Phase II · Preclinical Development of a Novel Gene Therapeutic for Inclusion Body Myositis | $1,877,616 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Development of optimized adeno-associated viral capsids for muscle gene therapy | $140,152 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Development of optimized adeno-associated viral capsids for muscle gene therapy | $140,152 | |
| Federal grant | Department of Health and Human Services · Phase II · Preclinical Development of a Novel Gene Therapeutic for Inclusion Body Myositis | $973,558 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of optimized adeno-associated viral capsids for muscle gene therapy | $134,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Preclinical validation of AVGN7 for treating obesity and type 2 diabetes mellitus. | $350,000 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1718 | Curve Therapeutics | — | — |
| 1719 | Peroxitech LLC | — | — |
| 1720 | SAMBA BIOLOGICS INC. | — | — |
| 1721 | AAVOGEN INC | — | — |
| 1722 | Emergo Therapeutics, Inc. | — | $4.0M |
| 1723 | Sensible Biotechnologies, Inc. | — | $15M |
| 1724 | Pulmocide | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Codon-optimized SMAD7 Gene Therapy To Treat And Prevent Muscle Wasting And To Enhance Muscle Massapplication
- Codon-optimized SMAD7 Gene Therapy To Treat And Prevent Muscle Wasting And To Enhance Muscle Massapplication
- Codon-optimized SMAD7 Gene Therapy To Treat And Prevent Muscle Wasting And To Enhance Muscle Massapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.